What to Do When an IBD Infusion or Injection Is Delayed

A delayed infusion or injection is one of the most common disruptions in inflammatory bowel disease care. An infusion center loses a chair, a prior authorization expires, a specialty pharmacy ships late, or a copay assistance card fails at the counter. The clinical question underneath all of those situations is the same: how long can this dose wait, and who has the authority to fix it? Treating the delay as a workflow with an ordered contact list and a written record turns a stressful week into a manageable one.

Why a Delayed Biologic Dose Is a Clinical Event, Not Just an Inconvenience

Interruptions in biologic therapy carry two distinct risks. The first is loss of disease control, since these drugs work by maintaining a steady blood concentration that suppresses intestinal inflammation, and NIDDK describes the goal of Crohn's treatment as bringing on and maintaining remission. The second is immunogenicity, meaning the immune system builds antibodies against the drug during the gap. The Remicade prescribing information reports that antibodies to infliximab develop in roughly 10% of patients on standard maintenance therapy, with a substantially higher incidence after drug-free intervals exceeding 16 weeks, and that antibody-positive patients clear the drug faster, respond less well, and experience more infusion reactions. Delays of a few days rarely matter. Delays measured in months change the risk picture.

Know Your Drug's Dosing Window Before You Make the First Call

The urgency of a delay depends entirely on which therapy you are on, so look up your own schedule before you call anyone. Infliximab is given as 5 mg/kg intravenously at weeks 0, 2, and 6, then every 8 weeks for Crohn's disease and ulcerative colitis. Vedolizumab is 300 mg at weeks 0 and 2, then every 8 weeks intravenously or 108 mg subcutaneously every 2 weeks from week 6. Ustekinumab uses a weight-based intravenous induction dose followed by 90 mg subcutaneously 8 weeks later and every 8 weeks thereafter. Adalimumab for Crohn's disease and ulcerative colitis moves to 40 mg every other week after induction, and its label instructs that a missed dose be administered as soon as possible, with dosing then resuming at the regular scheduled time. A delay during induction deserves faster escalation than a delay in year three of stable maintenance, because induction establishes the drug levels that maintenance is designed to preserve.

Work an Ordered Contact List Instead of Calling Everyone at Once

Delays have owners, and calling the wrong owner wastes days. Start with whoever physically administers or ships the drug, because they can usually identify the cause within one call. For infusions that is the infusion center scheduler, and for self-injected biologics it is the specialty pharmacy. If the cause is a lapsed or denied authorization, the second call goes to the prior authorization or benefits coordinator at your gastroenterology practice, since they submit the paperwork and can request an expedited review. The third call goes to your gastroenterologist's nurse or clinical team, who decide whether the gap is clinically acceptable and whether the dose should be rescheduled rather than skipped. Only after those three should you call the insurer directly, and when you do, ask for the reference number of the pending authorization and the decision deadline.

Document Every Call in a Format You Can Reuse

Insurance and pharmacy disputes are won with dates and names. For each call, record the date and time, the name and role of the person you spoke with, a reference or case number, the stated cause, and what they committed to do by when. Keep the originally scheduled dose date alongside the date the dose is actually given, because that pair of dates is what your gastroenterologist needs later to interpret symptoms, drug levels, or a loss of response. Delays are common enough to be a measurable driver of outcomes. An Inflammatory Bowel Disease Partners survey of 2,017 patients found that 72% had encountered an insurer-mandated barrier, 22% had experienced an actual gap in therapy because of insurance, and medication denials were associated with markedly higher odds of IBD-related surgery within a year.

When a Short Delay Becomes a Drug Holiday

If a gap stretches into months, restarting is a clinical decision that belongs to your gastroenterologist rather than a scheduler. The infliximab label notes that in a re-induction trial, 4% of patients receiving retreatment induction had serious infusion reactions compared with under 1% on continuous maintenance. A systematic review of infliximab infusion reactions found that late immune reactions such as serum sickness were repeatedly reported when infusions resumed after drug-free intervals longer than 12 weeks, and that patients with antibodies to infliximab carried roughly double the risk of acute infusion reactions. Restarting is still often successful. A real-world cohort of 76 patients restarted after breaks of six months or more reported 76% persistence at 14 weeks, with shorter holidays predicting better outcomes, and its authors recommend checking drug levels and antibodies one to three weeks after the first re-induction dose. Published restart algorithms and pharmacy guidance on managing infliximab after a drug holiday both center on that same monitoring step, consistent with AGA guidance supporting reactive therapeutic drug monitoring when disease is active.

Reduce the Odds of a Repeat Delay

Most delays are predictable, which means most are preventable. Prior authorizations have expiration dates, so ask your practice when yours renews and confirm it a month ahead rather than discovering the lapse at check-in. Book the next infusion appointment before leaving the current one, since chair availability is the constraint that fills first. Verify copay assistance enrollment annually, because these programs reset on a calendar year and a lapsed card frequently triggers a pharmacy hold. One analysis of 66 patients starting biologic therapy found an average of 30.5 days from request to approval and 45.3 days to the first infusion, with longer waits among patients on public insurance, and a 2022 survey of 373 gastroenterology providers reported that authorization requirements delay therapy, alter prescribing decisions, and lead to adverse events.

A delay handled well looks like a phone call to the right person within 24 hours, a written record of what was promised, and a clinician who knows the dose was late before your next visit rather than after it. The 2025 ACG ulcerative colitis guidelines emphasize monitoring response within 8 weeks of starting a therapy and making treatment decisions collaboratively, which requires that the treatment timeline your gastroenterologist sees matches the doses you actually received. A running log of scheduled dates, administered dates, and the reason behind every gap gives future decisions about dose escalation, drug level testing, or switching therapies something reliable to rest on.